An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

Elizabeth S. Waxman, RN, MSN, NP-C, AOCN®
The University of Texas MD Anderson Cancer Center

Posted: 11/21/2017
Expires: 11/21/2018
Estimated time to complete: 1 hour

Instructions for Earning CE credit

This activity has expired, credit is no longer available.

Full Session

Chapter 1
Introduction and Overview

Chapter 2
Current Treatment Paridigms

Chapter 3
Mechanisms of Action

Chapter 4
Case Study 1

Chapter 5
1st line treatment: Targeted Therapies

Chapter 6
Targeted Therapy Side Effects

Chapter 7
Targeted Therapy Resistance

Chapter 8
3rd line therapy - Targeted therapy

Chapter 9
Case Study 2

Chapter 10
Platinum Doublet Side Effects

Chapter 11
2nd Line Therapy

Chapter 12
Immunotherapy Side Effects

Chapter 13
3rd line therapy - Immunotherapy

Chapter 14
Conclusion

rowCount++; var rowCount = 0;

Full Session

Chapter 1
Introduction and Overview

Chapter 2
Current Treatment Paridigms

Chapter 3
Mechanisms of Action

Chapter 4
Case Study 1

Chapter 5
1st line treatment: Targeted Therapies

Chapter 6
Targeted Therapy Side Effects

Chapter 7
Targeted Therapy Resistance

Chapter 8
3rd line therapy - Targeted therapy

Chapter 9
Case Study 2

Chapter 10
Platinum Doublet Side Effects

Chapter 11
2nd Line Therapy

Chapter 12
Immunotherapy Side Effects

Chapter 13
3rd line therapy - Immunotherapy

Chapter 14
Conclusion

rowCount++;

Quick Tips

How do you identify and manage adverse events?

How do you interpret a patient’s therapeutic response to treatment?

What are the genetic variants in NSCLC, and how are they used to select treatment?

What is the current thinking on diagnosis and treatment of patients with squamous cell NSCLC?

What are the mechanisms of action of targeted treatments and immunotherapies?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.